HEART FAILURE IS A COMMON SEQUEL to pathological cardiac hypertrophy. Many proteins and genes are altered in cardiac hypertrophy (22) . Less is known about protein and gene expression in the transition from hypertrophy to heart failure. Gene array technologies allow us to investigate thousands of genes simultaneously and to compare gene expression pattern under different pathological conditions. Various studies analyzing nonfailing heart and end-stage dilated cardiomyopathy expression profiles have identified interesting known and unknown genes (6, 18) . We are investigating a double transgenic rat (dTGR) model harboring the human angiotensinogen and renin genes (15, 29, 30) . These rats develop hypertension, cardiac hypertrophy, proteinuria, and renal failure. Their mortality is ϳ50% at age 7 wk. All 7-wk-old dTGR show cardiac hypertrophy and preserved systolic function but impaired diastolic filling. However, a subset of animals develops terminal heart failure (THF), loses about up to one-quarter of their body weight within 2-3 days, and quickly dies thereafter (29, 30) . Their physical condition resembles the clinical features of heart failure with cachexia (3) . The molecular mechanisms that take place in a very few days from a hypertrophied heart to THF accompanied by cachexia are not understood. Gene expression studies are able to elucidate a large number of expected and undiscovered genes and pathways. The purpose of our study was to distinguish THF-dTGR from dTGR functionally and to possibly elucidate molecular mechanisms underlying the transition from compensated hypertrophy to THF with cachexia. We used an Affymetrix chip array approach to determine gene expression profiles. From our list of differentially expressed genes (239 increased and 150 decreased transcripts; THFdTGR vs. dTGR), we selected two pathways for detailed analysis. First, we investigated heat shock proteins (HSPs) and markers of inflammation, immunity, and tissue repair. Second, we focused on genes of the metabolic pathway that might be interesting not only for the cachetic but also for the cardiac phenotype of THF-dTGR.
METHODS
Experimental animals. Rats overexpressing the human renin and angiotensinogen genes have been described in detail (15, 29, 30) . dTGR were purchased from RCC (Füllinsdorf, Switzerland). Experiments were conducted in age-matched 4-wk-old male untreated dTGR, losartan (LOS)-treated dTGR (n ϭ 12; 10 mg⅐kg Ϫ1 ⅐day Ϫ1 in the diet for 3 wk), and nontransgenic Sprague-Dawley rats (SD) (Tierzucht Schönwalde, Schönwalde, Germany; n ϭ 8) after due approval from the Local Animal Authorities of the County of Berlin, Germany (permit no. G408/97). Untreated dTGR were divided in two subgroups, rats with cardiac hypertrophy (n ϭ 18) and rats with THF (n ϭ 8). We defined criteria for THF as follows: marked decline in physical activity (lethargy) and loss of body weight for 3 consecutive days. Both are criteria of the German Animal Care Authorities. Systolic blood pressure was measured by tail cuff under light ether anesthesia. We could not measure filling pressures or stroke volume directly but instead relied on echocardiography. Echocardiography (M-mode tracings at short axis; n ϭ 5/group) was performed using a commercially available system equipped with a 15-MHz phased-array transducer under light ether anesthesia (29) . Three measurements per heart were determined, averaged, and analyzed. Tissue Doppler with the sample volume in the basal septum in a four-chamber view was done to measure the velocity of the longitudinal cardiac movement at the basal septum, allowing assessment of diastolic filling. Velocity range, gain, and filter settings were optimized to detect low velocities, and the pulsed-wave Doppler spectrum was displayed at 200 mm/s. The measurements represent velocities of peak early (Ea) and late (Aa) diastolic expansion. The Ea-to-Aa ratio (Ea/Aa) is reported as an index of diastolic function. Urine samples were collected over 24 h. Urinary albumin was measured by ELISA (CellTrend). Rats were killed at age 7 wk. For RNA analysis tissues were snap frozen in liquid nitrogen, and for immunohistochemistry in Ϫ40°C cold isopentane, and stored at Ϫ80°C.
RNA isolation, Affymetrix microarray, and TaqMan analysis. Total RNA (5 animals/group) was isolated from the left ventricle with the use of Qiashredder and RNeasy spin columns, including chromosomal DNase digestion (Qiagen, Hilden, Germany). Twenty micrograms of total RNA were reverse transcribed into cDNA with the use of oligo(dT)24 primers containing a T7 RNA polymerase promoter. In vitro transcription was performed in the presence of biotin-labeled CTP and UTP (Enzo Diagnostics, Framingdale, NY) on doublestranded cDNA using Megascript T7 kit (Ambion, Huntingdon, UK). Parallel analysis of gene expression was carried out. Labeled cRNA were used as the target in the hybridization process. Hybridizations were performed overnight; gene chips were washed and stained with streptavidin-phycoerythrin. A laser-scanning technique determined the data, and pixel levels were analyzed with Affymetrix software (7) . Detailed protocols for data analysis of Affymetrix microarrays have been described (24) . The Affymetrix Gene-Chip U34A represents 8,800 genes and expressed sequence tags (Affymetrix, Woodburn Green, UK). Each gene was represented by the use of 20 perfectly matched (PM) and mismatched (MM) control probes. The MM probes acted as specificity controls that allowed the direct subtraction of both background and cross-hybridization signals. To determine the quantitative RNA abundance, the average of differences representing PM minus MM for each specific probe family was calculated, after discarding the maximum, the minimum, and any outliers beyond three standard deviations. Expression values were compared between the THF-dTGR and dTGR as well as LOS-treated and SD rats. The microarray data were prepared according to Minimum Information about a Microarray Experiment recommendations (9) , have been submitted in the Gene Expression Omnibus (GEO) database, and can be accessed at http://www.ncbi.nlm.nih.gov/geo. The GEO accession no. for the platform is GSE1557. The four samples can be retrieved with GEO accession nos. GSM26710, GSM26711, GSM26712, and GSM26713.
TaqMan RT-PCR confirmed the gene expression level from the left ventricle. TaqMan analysis was conducted according to the manufacturer's instructions, using an Applied Biosystems 7700 Sequence Detector (Applied Biosystems, Darmstadt, Germany). Each sample (n ϭ 6-8/group) was measured in triplicate, and expression level was normalized to 18S expression with the standard curve method. The TaqMan primer sets are listed in TAQMAN PROBE AND PRIMER SETS USED.
For ␣-myosin heavy chain (MHC), ␤-MHC, atrial natriuretic peptide (ANP), and sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA)2a, quantitative RT-PCR amplification was carried out in 25 l of SybrGreen PCR Master Mix (Applied Biosystems) containing 0.3 or 0.9 mol/l primer and 1 l of the reverse transcription reaction in a 5700 Sequence Detection System (Applied Biosystems). Thermal cycling conditions comprised an initial denaturation step at 95°C for 10 min, followed by 95°C for 15 s and 65°C for 1 min for 40 cycles. The mRNA expression was standardized to the hypoxanthine phosphoribosyl transferase gene as a housekeeping gene (39). Fig. 1 . A: systolic blood pressure was higher in terminal heart failure (THF)-double transgenic rats (dTGR) and dTGR than in losartan (LOS)-treated dTGR and nontransgenic Sprague-Dawley rats (SD; P Ͻ 0.001). THFdTGR tended to have increased blood pressure levels compared with dTGR (P ϭ 0.051). B: THF-dTGR and dTGR showed increased 24-h albuminuria compared with both other groups (P Ͻ 0.001), whereas LOS-treated dTGR were not different from SD. C: body weight was decreased in THFdTGR compared with all other groups. D: a representative cardiac section shows an area of fresh myocardial necrosis in THF-dTGR. Results are means Ϯ SE; n ϭ 6-10. *P Ͻ 0.05 vs. THF-dTGR. #P Ͻ 0.05 vs. dTGR.
Immunohistochemistry. Ice-cold acetone-fixed cryosections (6 m) were stained by immunofluorescence and the alkaline phosphatase (APAAP) technique as described earlier (29, 30) . The sections were incubated with the monoclonal antibodies anti-CD4 (Pharmingen), anti-ED-1 (Serotec), and anti-CD86 (Pharmingen) and the polyclonal antibodies anti-IL-6, anti-HSP70 (Stressgene), and anti-fibronectin (Paesel). Cy3 and FITC secondary antibodies (Dianova) were used for colocalization stainings. Semiquantitative scoring of infiltrated cells and matrix expression was performed as described earlier (30) .
Statistical analysis. Data are presented as means Ϯ SE. Statistically significant differences in mean values were tested by ANOVA, with repeated measures when appropriate, followed by Student's t-test. A value of P Ͻ 0.05 was considered statistically significant. The data were analyzed using Statview statistical software. For Affymetrix microarray analysis, we used the Affymetrix microarray suite program. Genes with P value Ͻ 0.01 were considered to be differentially expressed between THF-dTGR and dTGR as well as dTGR and LOS-treated-dTGR.
RESULTS
We found that a subset of untreated dTGR developed cachexia and signs of cardiac failure (THF-dTGR). In contrast, a preterminal dTGR subset exhibited cardiac hypertrophy without loss of body weight. At death, THF-dTGR had blood pressures of 228 Ϯ 7 mmHg, which was slightly higher than untreated dTGR (197 Ϯ 5 mmHg; P ϭ 0.051). Both dTGR subgroups showed significantly elevated systolic blood pressure levels compared with LOS-dTGR and nontransgenic SD rats (141 Ϯ 6 and 112 Ϯ 4 mmHg, respectively; P Ͻ 0.01; Fig.  1A ). THF-dTGR and preterminal dTGR showed severe albuminuria. LOS treatment reduced albuminuria toward the SD level (Fig. 1B) . THF-dTGR lost about 10-20% of their body weight within the last 2-3 days (Fig. 1C) , leading to decreased body weight compared with all other groups (P Ͻ 0.05). All THF-dTGR showed areas of myocardial necrosis. A represen- Fig. 2 . A: THF-dTGR and dTGR showed increased cardiac mass compared with both other groups (P Ͻ 0.01), whereas LOS-treated dTGR were not different from SD. B and C: heart weight-to-tibia length as well as heart-to-body weight ratios were increased in THF-dTGR and dTGR compared with LOS-treated dTGR and SD. Because of loss of body weight, heart-to-body weight ratio was further increased in THF-dTGR vs. dTGR. D: cardiac fibronectin expression in THF-dTGR and dTGR was significantly increased compared with LOS-treated dTGR and SD. Results are means Ϯ SE; n ϭ 6-10. *P Ͻ 0.05 vs. THF-dTGR. #P Ͻ 0.05 vs. dTGR. tative example is given in Fig. 1D . THF-dTGR and dTGR both showed increased cardiac mass ( Fig. 2A ) and heart-to-tibia ratio ( Fig. 2B ) as well as heart-to-body weight ratio ( Fig. 2C ) compared with LOS-treated dTGR and SD. Despite identical heart weights, THF-dTGR also showed a higher heart-to-body mass ratio compared with preterminal dTGR (Fig. 2C ), indicating that THF-dTGR did not lose cardiac mass during cachexia development. Matrix protein deposition, determined as fibronectin staining by immunofluorescence, showed that fibronectin was markedly expressed in THF-dTGR and dTGR compared with SD. LOS-dTGR showed markedly reduced fibronectin expression toward SD staining (Fig. 2D) .
Several hypertrophy markers were increased in THF-dTGR and preterminal dTGR. ANP mRNA expression (Fig. 3A) in the left ventricles was increased in THF-dTGR and dTGR compared with LOS-treated dTGR and SD. Whereas ANP mRNA expression was similar in THF-dTGR and dTGR, left ventricles from THF-dTGR showed significantly increased c-fos expression compared with all groups (Fig. 3B ). Furthermore, both groups showed a shift of ␣-MHC to ␤-MHC phenotype, indicating cardiac hypertrophy (Fig. 3 , C-D). TaqMan RT-PCR also confirmed that the SERCA2a was decreased in THF-dTGR and dTGR compared with both other groups. LOS treatment restored the decreased expression of THFdTGR and dTGR (Fig. 3E) . Echocardiography confirmed the increased left ventricular wall thickness in preterminal dTGR and THF-dTGR, which was reduced to the SD level by LOS (Table 1) . Using mitral valve Doppler, we demonstrated that preterminal dTGR and THF-dTGR showed signs of diastolic dysfunction (Ea Ͻ Aa), again normalized by LOS. Systolic function, measured by fractioning shortening, was similar in all four groups.
We compared the expression profiles of THF-dTGR vs. dTGR with preterminal cardiac hypertrophy with Affymetrix gene chips to better understand the transition from hypertrophy to heart failure with cachexia. We identified 239 transcripts that were significantly increased and 150 transcripts that were decreased in THF-dTGR compared with dTGR. Table 2 lists 56 selected known transcripts that were differentially ex- pressed in THF-dTGR compared with dTGR. Various genes determining immunity and inflammation and promoting extracellular matrix formation, coagulation, and tissue repair were increased. Interestingly, several genes regulating mitochondrial energy production were decreased.
A variety of genes involved in energy metabolism were altered between THF-dTGR and dTGR. Our array data show that the insulin-dependent glucose transporter GLUT4 was decreased. In contrast, GLUT1 was increased in THF-dTGR compared with dTGR. Two other mRNAs encoding glycolytic enzymes were elevated, the glycolytic key enzyme phosphofructokinase (PFK) and GAPDH. We confirmed some of these changes with TaqMan PCR. GLUT1, GLUT4, and PFK mRNA expression is shown in Fig. 4 . Our chip experiment also showed that phosphorylase kinase, an enzyme involved in glycogen catabolism, and glucose-6-phosphatase, which is involved in gluconeogenesis, were decreased twofold. ATP citrate lyase, necessary for fatty acid synthesis, was twofold increased. Mitochondrial respiratory chain components (cytochrome B, cytochrome c oxidase, ATP synthase) were decreased in THF compared with dTGR. In addition, mRNAs involved in lipid catabolism (long-chain acyl-CoA synthetase, carnitine palmitoyltransferase I, longchain acyl-CoA dehydrogenase) were diminished.
We next analyzed the expression pattern comparing both hypertrophic groups (THF-dTGR and dTGR) with chronically LOS-treated dTGR (Table 3 ). Cardionatrin precursor, also known as ANP, a marker of cardiac hypertrophy, genes of the cell cycle (cyclin D3, cyclin D2, cyclin D), HSPs (HSP70, HSP27), and genes of the MAPK pathway (heparin-binding EGF-like growth factor, p38 MAPK, c-fos, junB, fra) as well as various transcription factors (c-fos, fra, c-myc) were significantly increased in the left ventricles, whereas some nuclear receptors (growth hormone receptor, retinoic X receptor-␥) were decreased.
We then selected various genes for further investigation. TaqMan PCR confirmed the relative expression pattern of the HSP70 (Fig. 5A), HSP27 (Fig. 5A ), IL-6 (Fig. 6A) , and hemeoxygenase (HO)-1 (Fig. 6C) . In THF-dTGR, the HSP70 expression was induced 6-fold compared with dTGR and ϳ10-fold compared with LOS-dTGR and SD, respectively. Immunohistochemistry showed that HSP70 immunoreactivity (Fig.  5B) was detected in the media of THF-dTGR and dTGR. In addition to the vascular localization, THF-dTGR showed areas with patchy areas of myocardial necrosis that also expressed HSP70. These areas were prominent in THF-dTGR and rare in dTGR. In LOS-dTGR and SD, HSP70 was not detectable in the myocardium. IL-6 and HO-1 mRNA showed responses very similar to HSP70 mRNA. IL-6 immunoreactivity was increased in the media of THF-dTGR and dTGR compared with LOS-dTGR and SD (data not shown). IL-6 and HSP70 immunostaining was coexpressed in the vascular wall of a coronary artery (Fig. 6B) . Because the proinflammatory IL-6 was increased, we analyzed cell infiltration into the heart more closely. Monocytes and macrophages (ED-1ϩ cells; Fig. 6D ), CD4 T-cells (Fig. 6E) , and CD86ϩ cells (data not shown) infiltrated more frequently into the hearts of THF-dTGR and dTGR compared with LOS-dTGR and SD.
DISCUSSION
We found distinct differences in myocardial gene expression in THF-dTGR, dTGR, LOS-dTGR, and SD controls. THFdTGR were indeed terminally ill. Some rats died before we could euthanize them. THF-dTGR were slightly more hypertensive and clearly weighed less than dTGR. Echocardiography demonstrated similar systolic function; however, the diastolic function was poorer and matrix protein expression was increased in THF-dTGR. When we compared THF-dTGR with dTGR in terms of gene expression, we identified 239 transcripts that were increased in expression and 150 transcripts that were decreased. These transcripts presumably represent the genes and gene families that are important to THF with accompanying cachexia.
Hypertrophy occurs as a compensatory, adaptive response to increased workload by which myocardial wall stress is restored. However, cardiac hypertrophy is an independent risk factor for the development of myocardial infarction, sudden death, and congestive heart failure. After a prolonged period of compensatory adaptation of cardiac hypertrophy with a restored wall stress, myocardial exhaustion occurs with heart failure development. The underlying mechanisms of this change from compensated hypertrophy to heart failure are not known. However, an alteration in energy metabolism may contribute to this disease evolution. Taegtmeyer (43) formed the concept of "genetics of energetics." This hypothesis implicates a dynamic interaction between gene expression, energy substrate metabolism, and heart function. A certain metabolic status induces the activity of transcription factors and/or regulates metabolic gene transcription, which alters cardiac function and vice versa.
A dynamic adaptation to cardiac hypertrophy and failure has been characterized for sarcomeric gene expression. This adaptation is characterized by a switch of sarcomeric proteins from "adult" to "fetal" isoform, the induction of growth factors, and the reexpression of protooncogenes. We showed that IL-6, c-fos, and ANP are increased in the dynamic process from compensated hypertension to THF. We also found the downregulation of ␣-MHC in parallel with a ␤-MHC mRNA increase, representing the switch from adult to fetal isoform. In addition, SERCA2a was decreased in hypertrophied and failing dTGR hearts, which was reversed by chronic LOS treatment. In heart failure, abnormal calcium handling contributes to contractile dysfunction (16) . The steady-state levels of SERCA2a are reduced in human heart failure due to dilated cardiomyopathy. Inducible SERCA2a expression improves calcium handling and reverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy (6, 42) . A recent study reported that IL-6 reduced SERCA mRNA and induced ANP mRNA expression in cultured rat ventricular myocytes. The investigators concluded that cardiac hypertrophy may result from the imbalance of both ANP and SERCA transcription levels, caused by elevated IL-6 expression (45). Furthermore, clinical studies have shown that circulating levels of IL-6 and other IL-6-related cytokines are increased in patients with congestive heart failure (37, 49) . IL-6 is a pleiotropic cytokine with varying effects on cells of the immune system and other tissues. Angiotensin II stimulates IL-6 production in vascular smooth muscle cells and cardiac myocytes (36, 48) . We demonstrated that IL-6 mRNA is enhanced in THF-dTGR left ventricles. Immunohistochemistry demonstrated IL-6 protein in smooth muscle cells of cardiac vessels colocalizing with HSP70, which is the highest differentially expressed gene in our chip experiment. The promoter/enhancer region of IL-6 contains response elements for nuclear factor (NF)-B, activator protein (AP)-1, and CCAAT/enhancer-binding protein (C/ EBP) (11, 25) . In the present study, components of the AP-1 complex, C/EBP-␤ and -␦, and Janus kinase/signal transducers and activators of transcription were differentially expressed in THF-dTGR and dTGR compared with LOS-treated dTGR and SD. We have previously shown that cardiac NF-B and AP-1 DNA-binding activity is increased in dTGR. In a positivefeedback loop, gp130/IL-6 signaling induces C/EBP expression (20) . HSPs function as molecular chaperones or proteases (8) . They are induced by environmental stress, including heat shock, oxidative stress, ischemia, and reperfusion. HSPs interact with diverse substrates to assist in their folding and to prevent the appearance of folding intermediates that lead to misfolded or damaged molecules. Angiotensin II induces the expression of HSPs in cultured vascular smooth muscle cells, aorta, and kidney. HSP70 protects cells against apoptosis, THF-dTGR showed the strongest signal, whereas LOS-treated dTGR and SD showed almost no signal. Inset: prominent immunoreactivity in THF-dTGR myocytes, which was rare in dTGR and not found in LOS-treated dTGR and SD hearts.
perhaps by binding to proapoptotic proteins (28) . Similar function has been attributed to HSP27 (8) . Also of interest is the fact that HSPs participate in specific protective immunity (27) . The molecules can elicit cytokine production and adhesion molecule expression. They can deliver maturation signals and peptides to antigen presenting cells through receptormediated interactions. Both innate and acquired immunity are involved in our angiotensin II-mediated organ damage in this model (30) . Asea et al. (4) showed that HSP70 acts as a cytokine, activates NF-B, and upregulates the expression of proinflammatory cytokines TNF-␣, IL-1␤, and IL-6 in human monocytes. Infiltration of monocytes/macrophages is a typical feature of our transgenic model (29, 30) . In the present study, we could also show that LOS treatment prevented infiltration of macrophages and T-cells as well as IL-6. We found high expression of HSP70 in cardiac vessel walls and colocalization with IL-6. HSP70 was highly expressed in presumably dying cardiomyocytes in THF-dTGR. Barrans et al. (6) showed in a microarray study that HSP70 was also upregulated in patients with end-stage dilated cardiomyopathy.
Studies in spontaneously hypertensive rats (12) and in patients with essential hypertension (17) have demonstrated a decrease in myocardial fatty acid utilization. Sack and Kelly (35) were the first to report that a number of genes encoding for the cardiac fatty acid oxidation enzymes (medium-chain acylCoA dehydrogenase, long-chain acyl-CoA dehydrogenase, and 3-OH long-chain acyl-CoA dehydrogenase) are downregulated in the hypertrophied and failing myocardium. During hypertrophy, the primary myocardial energy source switches from fatty acid ␤-oxidation to glycolysis, a reversion to the fetal energy substrate preference pattern (14, 44) . Razeghi et al. (32) have characterized the expression profile of 13 key energy metabolism regulators in fetal, nonfailing, and failing adult hearts. Interestingly, they found that failing adult hearts reverted to the fetal phenotype profile by the downregulation of the adult genes rather than the upregulation of fetal genes. We also observed a downregulation of several adult genes, for example ␣-MHC, GLUT4, long-chain acyl-CoA dehydrogenase, and carnitine palmitoyltransferase I. In contrast to the study of Razeghi et al., in our dTGR model, ␤-MHC and GLUT1 were increased. We performed our rat experiments from week 4 to 7, a phase in which these relatively juvenile animals are still growing. Therefore, we cannot exclude the possibility that the age of our rats might have had an effect.
Although the failing heart relies on glucose for energy production, enzymes controlling glucose utilization, especially glucose transport, phosphorylation, and oxidation are reduced. Myocardial glucose uptake relies strongly on the glucose transporters GLUT1 and GLUT4 (1, 31) . We found that the left ventricles of THF-dTGR showed markedly increased GLUT1 mRNA. These values were less strongly but nonetheless enhanced in dTGR compared with SD rats. Elevated GLUT1 mRNA expression is not surprising, since GLUT1 is regulated via the MAPK/AP-1 pathway. We showed earlier that AP-1 DNA binding activity is increased in dTGR hearts (29) . In contrast, GLUT4 was decreased in THF-dTGR rats compared with all other rat groups. Experiments in GLUT4-deficient mice suggest an important role of GLUT4 in the development of cardiac hypertrophy. A complete GLUT4 knockout mouse and a cardiac-specific knockout both showed cardiac hypertrophy (2, 21) . Cardiac-specific GLUT4 knockout mice did not exhibit differences in glucose tolerance, insulin, or other metabolic substrates (2) . These findings indicate that GLUT4 plays a role in the development of hypertrophy independently of its metabolic function. On the other hand, exogenous glycolysis is accelerated (40) . On the mRNA level, we found that the key enzyme of the glycolytic metabolic pathway, PFK, was increased in THF-dTGR and dTGR. On the protein level, in cardiac muscle cells ATP and citrate concentrations are so high that the enzyme would be completely inhibited and therefore could not act as an allosteric regulated key enzyme (38) . Interestingly, PFK mRNA was markedly higher in spontaneously hypertensive rats compared with control rats and remained unchanged by exercise training-induced cardiac hypertrophy compared with controls (19) .
Mitochondrial function changes during development and is altered in failing human hearts (10, 32) . We found a decrease in three of seven mitochondrial multicomplex units in THFdTGR with our chip approach (cytochrome B, cytochrome c oxidase, ATP synthase). Ruppert et al. (33) recently described similar results by sequencing novel point mutations in the mitochondrial NADH dehydrogenase and cytochrome c oxidase detected in patients with dilated cardiomyopathy. Mutations altering the function of the respiratory chain enzyme subunits could be relevant for the pathogenesis of cardiac hypertrophy. In addition, enzyme activities of the cytochrome c oxidase and NADH dehydrogenase in pigs with a naturally occurring hypertrophic cardiomyopathy were lower than those in the controls (23) . Aside from the reduced expression, one alternative mechanism for the loss of mitochondrial enzyme activity might be related to reactive oxygen species (ROS)-mediated mitochondrial DNA damage (46) . ROS production also contributes to the development of heart failure. Xanthine oxidase activity is enhanced during heart failure (13) . Various groups have reported that xanthine oxidase inhibition improved mechanoenergetic coupling in pacing-induced heart failure (13, 34) . We found earlier that oxypurinol, a xanthine oxidase inhibitor, reduced ROS generation and ameliorated end-organ damage in the dTGR model (26) . Thus mitochondrial enzyme deficiency and ROS-induced mitochondrial DNA damage might be involved in the pathogenesis of cardiac hypertrophy.
In summary, genes implicated in energy metabolism were highly represented in our gene expression experiment. We found the expression of these genes to be changed in THFdTGR and dTGR compared with other groups. Recent evidence suggests that energy substrate metabolism forms the link between gene expression and functional changes (contractile dysfunction) of the heart. Dysregulation of genes of fatty acid metabolism and glucose metabolism contributes to a state of starving of the failing heart, which is decremental in cardiac hypertrophy with an increased energy demand. Therapy aimed at modulating energy metabolism could be a new alternative approach to the improvement of a failing myocardium. Drugs that shift energy metabolism away from fatty acids to carbohydrates have been developed and are currently under trial (5, 41) . Ventura-Clapier et al. (47) suggest that such a therapeutic strategy will cope with the proposal that "it is worthwhile to feed a tired energy-starved horse rather than whip the horse with inotropic agents." Inhibition of the renin-angiotensin system has been shown to be beneficial in reversing the structural changes in hypertension and THF. However, the effect of renin-angiotensin system inhibition on the metabolic changes remains controversial and must be elucidated in future studies.
